Lupus (SLE) trials in France

In France 51 Also abroad 354

51 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Where
Montpellier, Paris, Paris Cedex 13, Toulouse, Toulouse Cedex 9, Tours Cedex 9
Age
12 years to 100 years
People
550 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00
Phase 3Taking people
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Where
Besancon Cedex, Bordeaux, Grenoble Cedex 9, Marseille, Poitiers, Toulouse Cedex 9
Age
18 years to 100 years
People
348 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06711887 · EU 2024-515280-60-00
Phase 1Taking people
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Where
Lyon Cedex 03, Poitiers, Toulouse Cedex 9
Age
18 years to 75 years
People
46 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT07629583 · EU 2025-522904-26-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Where
Lille, Lyon, Paris Cedex 20, Rouen Cedex, St Etienne Cedex 2
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Where
Bordeaux Cedex, Clermont-Ferrand, Dijon, Paris, Pessac
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00
Phase 2Taking people
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Where
Le Kremlin-Bicetre, Paris, Toulouse Cedex 9
Age
5 years to 17 years
People
40 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05039619 · EU 2023-505825-15-00
Phase 3Taking people
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Where
Caen Cedex 9, Grenoble Cedex 9, Le Mans Cedex 9, Lyon Cedex 04, Paris, Toulouse Cedex 9
Age
18 years to 75 years
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Where
Bordeaux, Le Kremlin-Bicetre, Le Mans Cedex 9, Montpellier Cedex 5, Paris, Strasbourg Cedex
Age
16 years and over
People
450 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00
No phaseTaking people
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Where
Bordeaux, Paris, Strasbourg
Age
16 years and over
People
223 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07175285
Phase 1/2Not yet taking people in France
Phase 1/2 study to evaluate the safety, pharmacokinetics, and preliminary efficacy of SAR447998 in adults with refractory Systemic Lupus Erythematosus or Rheumatoid Arthritis
Where
Marseille, Montpellier Cedex 5, Pessac
Age
18 years and over
People
10
Run by
Sanofi-Aventis Recherche & Developpement
See details and how to join2026-526117-28-00 · EU 2026-526117-28-00
Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Bordeaux, Nantes, Paris, Poitiers, Rennes, Strasbourg, Toulouse
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 1Taking people
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Where
Bordeaux
Age
18 years to 60 years
People
90 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06975787 · EU 2024-518288-37-00
Phase 3Not yet taking people in France
Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Beneﬁted from Continued Treatment.
Where
Bordeaux Cedex, Paris, Strasbourg Cedex 2, Toulouse Cedex 9
People
340 worldwide
Run by
AstraZeneca AB
See details and how to join2026-526419-13-00 · EU 2026-526419-13-00
Phase 1Taking people
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
Where
Nantes, St Etienne Cedex 2, Toulouse Cedex 9
Age
18 years to 70 years
People
24 worldwide
Run by
Cullinan Therapeutics Inc.
See details and how to joinNCT06613360 · EU 2024-518780-36-00
Phase 1Taking people
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Where
Bordeaux, Montpellier, Nancy, Paris, Strasbourg Cedex 2, Toulouse Cedex 9
Age
18 years to 70 years
People
72 worldwide
Run by
AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00
Phase 3Enrolling by invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Where
Bordeaux, Le Kremlin-Bicetre, Le Mans Cedex 9, Montpellier Cedex 5, Paris, Strasbourg Cedex
Age
16 years and over
People
760 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00
Phase 1Not yet taking people in France
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Where
Montpellier, Paris
Age
18 years and over
People
60 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07873931
Phase 1/2Taking people
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Where
Marseille Cedex 05, Paris, Paris Cedex 18, Poitiers
Age
12 years to 65 years
People
28 worldwide
Run by
Cabaletta Bio
See details and how to joinNCT06121297 · EU 2023-507613-10-01
Phase 3Enrolling by invitation
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
Where
Bordeaux, Clermont-Ferrand, Montpellier
Age
18 years and over
People
864 worldwide
Run by
Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00
Phase 2Taking people
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Where
Le Kremlin-Bicêtre, Lille, Lyon, Lyon Cédex 3, Marseille, Paris, Strasbourg, Toulouse
Age
18 years to 75 years
People
220 worldwide
Run by
Amgen
See details and how to joinNCT06570798
Phase 3Taking people
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Where
Clermont-Ferrand, Lyon Cedex 03, Marseille, Nancy, Paris, Saint-Pierre, St Denis, Talence, Toulon Cedex 9, Tours
Age
18 years and over
People
113 worldwide
Run by
AstraZeneca AB
See details and how to join2025-523670-17-00 · EU 2025-523670-17-00
Phase 3Taking people
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Where
Bordeaux, Bron, Le Kremlin Bicetre Cedex, Lille, Toulouse Cedex 9
Age
5 years to 17 years
People
100 worldwide
Run by
AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00
Phase 3Taking people
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Where
Clermont-Ferrand, Lyon, Marseille, Paris, Pessac, Saint-Denis, Saint-Pierre, Toulon, Tours, Vandœuvre-lès-Nancy
Age
18 years to 70 years
People
245 worldwide
Run by
AstraZeneca
See details and how to joinNCT07430306
Phase 3Taking people
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)
Where
Le Kremlin Bicetre Cedex, Nantes, Strasbourg Cedex, Tours
Age
18 years and over
People
147 worldwide
Run by
Bristol-Myers Squibb Services Unlimited Company
See details and how to join2022-500699-76-00 · EU 2022-500699-76-00
No phaseTaking people
Anifrolumab Malignancy and Serious Infections Study
Where
Charenton-le-Pont
Age
18 years to 130 years
People
3,506 worldwide
Run by
AstraZeneca
See details and how to joinNCT07000110